Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Merai, Ankit H.
- New Approaches to Antiretroviral Therapy - Raltigravir
Abstract Views :206 |
PDF Views:0
Authors
Affiliations
1 Smt. B. N. B. Swaminarayan Pharmacy College, Salvav, Vapi, IN
1 Smt. B. N. B. Swaminarayan Pharmacy College, Salvav, Vapi, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 3, No 2 (2011), Pagination: 58-66Abstract
AIDS is a disease caused by the retrovirus Human Immunodeficiency Virus (HIV) and is characterized by the profound immunosuppression that leads to the opportunistic infection, secondary neoplasm and neurologic manifestation. The magnitude of this modern plague is truly staggering. By the end of the 2008, more than 190000 causes of ADIS have been reported in the USA, AIDS is a global problem worldwide. AIDS has now been reported from more 193 countries.
Here we introduce recent therapies used in the treatment of AIDS, like highly active antiretroviral therapy. Also here we introduce drugs clinical trial like BT378/r and HIV vaccine. Our main focus is to high light an integrase inhibitor-Raltegravir which is a new category of drug.
By reviewing Raltegravir's mechanism, pharmacological parameter we conclude that an integrase inhibitor which is active against retrovirus, found to be more beneficial compare to other currently use drugs, and also be found to be effective against resistive subject and increase their like livelihood.
Keywords
Integrase Inhibitor, Raltegravir.
References
- Harsh M. Textbook Of Pathology. 2006;4:52 -53.
- Thomas J., Gordan A. Pathophysilogy Concepts and Applications Of Health care Professionals 2004;5:115-116.
- Padmaja U. Textbook Of Medical Pharmacology. 2009;2:407-410.
- Katzung. Basic and Clinical Pharmacology. 2007;10:799-801.
- Alfred G.G. The Pharmacological Basis Of Therapeutics. 2006;10:1341-1351.
- Landman R. et al. Evaluation at 6 months of a Once-a-Day HAART Regimen in Treatment-Naive HIV-1-Infected Adults in Senegal (ANRS 12-04 Study). Abstract 491, 8th Conference on Retroviruses and Opportunistic Infections.
- Diop Y. et al. Prospective Trials of CBV + IDV in West Africa [Cote-d'Ivoire], Abstract 492, 8th Conference on Retroviruses and Opportunistic Infections.
- Rang H.P. et al. Pharmacology. Churchill Livingstone.2003;5:659-665.
- www.nari_icmr.resin/antiretroviral_fag.html.National AIDS Research Institute, Pune, India.(viewed on 01 May 2006)
- Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H. , Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect. 2005;191:654-665.
- Pitisuttithum P., Gilbert P., Gurwith M. et al. Randomized double-blind placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect. 2006;194:1661-1671.
- http:// www.link.med.ed.ac.uk, HIV and aids introduction. (viewed on 22 December 2009)
- http://www.rxlist.com , Rxlist, Raltegravir. The internet drug index. (viewed on 10 Nov 2008)
- Grinstein., Beatriz., et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multi-drug resistant virus: a phase II randomized controlled trial. The Lancet. 2007;369:1261-1269.
- AIDSMEDS.com 7 August 2007. http://www.aidsmeds.com/archive/MK-0518_1639.shtml (viewed on 22 December 2009)
- Markowitz M., Nguyen B.Y., Gotuzzo E. et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. 2007;46(2):125–133.
- Stephenson J. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus. JAMA. 2007;14:1535.
- Faster Viral Decay with Raltegravir - The Body http://www.the body.com/content/art42654.html. (viewed on 24 December 2009)
- Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients with Previous Complete Viral Suppression. ClinicalTrials.gov Available at http://clinicaltrials.gov/ct2/showNCT00554398. (viewed on 24 December 2009)
- www.hivanhepatitis.com, Raltegravir (isentress) (viewed on 24 December 2009).
- Natap.org - Conference Reports: 10th European AIDS Conference. MK-0518, the First Integrase Inhibitor for HIV, No Blarney. Available at: http://www.natap.org/2005/EACS/eacs_3.htm. Accessed 06/30/08. (viewed on 25 December 2009).
- HIV and Hepatitis.com - Merck Announces Interim Results from Phase II Study of MK-0518, an Investigational Oral HIV Integrase Inhibitor. Available at:http://www.hivandhepatitis.com/2006icr/croi/docs/021006_b.html. (viewed on 22 December 2009).
- Scott A; Daniel; rouzioux; Acquired Immune Deficiency Syndrome. JAIDS. 2007;46(2):125-133.
- Merck and Company – Isentress prescribing Information, May 2008, p. 3. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08. (viewed on 25 December 2009).
- Merck and Company - FDA Approves Isentress (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor [Press Release], October 12,2007. Available at: http://www.merck.com/newsroom/press_releases/product/2007_1012.html. Accessed 06/30/08 (viewed on 27 December 2009).
- Merck and Company - Isentress Prescribing Information, May 2008, p. 4. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08 (viewed on 27 December 2009).
- Merck and Company - Isentress Prescribing Information, May 2008, p. 2. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08. (viewed on 27 December 2009).
- Intersci Conf Antimicrob Agents Chemother - 46th,(2006). Abstract H-1383.
- Merck and Company - Isentress Prescribing Information, May 2008, p. 1-2. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08(viewed on 27 December 2009).
- De clerk., Vandamme E., A-M combination Therapy of AIDS. Birkhauser verlag; Germany in 2004.
- Merck and Company - Isentress Prescribing Information ( May 2008), p. 1. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08 (viewed on 27 December 2009).
- Merck and Company - Isentress Prescribing Information ( May 2008), p. 13. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08. (viewed on 27 December 2009).
- Merck and Company - Isentress Prescribing Information ( May 2008), p. 7. Available at:http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf. Accessed 06/30/08. (viewed on 27 December 2009).
- Cooper D., Gatell J., Rockstroh J. et al. Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. Oral abstract 105LBa. http://www.retroconference.org/2007/Abstracts/30687.html (viewed on 2 January 2010).
- Steigbigel R., Kumar P., Eron J. et al. Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. Oral abstract 105LB. http://www.retroconference.org/2007/Abstracts/30688.html (viewed on 2 January 2010).
- http://www.futuremedicine.com, Future HIV therapy. 2008 (May); 2(3);217-227(viewed on 2 January 2010).